Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis
BackgroundTo investigate the factors that have significant impact on the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection and vaccination induced immune response in rheumatoid arthritis (RA).MethodsSerological response was measured by quantifying anti-SARS-CoV-2 specific antib...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.960001/full |
| _version_ | 1828105768278163456 |
|---|---|
| author | Dora Nemeth Dora Nemeth Dora Nemeth Hajnalka Vago Hajnalka Vago Laszlo Tothfalusi Zsuzsanna Ulakcsai David Becker Zsofia Szabo Bernadett Rojkovich Bela Merkely Bela Merkely Gyorgy Nagy Gyorgy Nagy Gyorgy Nagy Gyorgy Nagy |
| author_facet | Dora Nemeth Dora Nemeth Dora Nemeth Hajnalka Vago Hajnalka Vago Laszlo Tothfalusi Zsuzsanna Ulakcsai David Becker Zsofia Szabo Bernadett Rojkovich Bela Merkely Bela Merkely Gyorgy Nagy Gyorgy Nagy Gyorgy Nagy Gyorgy Nagy |
| author_sort | Dora Nemeth |
| collection | DOAJ |
| description | BackgroundTo investigate the factors that have significant impact on the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection and vaccination induced immune response in rheumatoid arthritis (RA).MethodsSerological response was measured by quantifying anti-SARS-CoV-2 specific antibodies, while the cell-mediated response was measured by a whole-blood test quantifying the interferon (IFN)-γ response to different SARS-CoV-2-specific domains.ResultsWe prospectively enrolled 109 RA patients and 43 healthy controls. The median time (IQR) between the confirmed infection or the last vaccination dose and the day when samples were taken (“sampling interval”) was 3.67 (2.03, 5.50) months in the RA group. Anti-Spike (anti-S) specific antibodies were detected in 94% of RA patients. Among the investigated patient related variables, age (p<0.004), sampling interval (p<0.001), the brand of the vaccine (p<0.001) and targeted RA therapy (TNF-inhibitor, IL-6 inhibitor, anti-CD20 therapy) had significant effect on the anti-S levels. After covariate adjustment TNF-inhibitor therapy decreased the anti-S antibody concentrations by 80% (p<0.001). The same figures for IL-6 inhibitor and anti-CD20 therapy were 74% (p=0.049) and 97% (p=0.002), respectively. Compared to subjects who were infected but were not vaccinated, the RNA COVID-19 vaccines increased the anti-S antibody levels to 71.1 (mRNA-1273) and 36.0 (BNT162b2) fold (p<0.001). The corresponding figure for the ChAdOx1s vaccine is 18.1(p=0.037). Anti-CCP (anti-cyclic citrullinated peptides) positive patients had 6.28 times (p= 0.00165) higher anti-S levels, than the anti-CCP negative patients. Positive T-cell response was observed in 87% of the healthy volunteer group and in 52% of the RA patient group. Following vaccination or infection it declined significantly (p= 0.044) but more slowly than that of anti-S titer (6%/month versus 25%). Specific T-cell responses were decreased by 65% in patients treated with anti-CD20 therapy (p=0.055).ConclusionOur study showed that the SARS-CoV-2-specific antibody levels were substantially reduced in RA patients treated with TNF-α-inhibitors (N=51) and IL-6-inhibitor (N=15). In addition, anti-CD20 therapy (N=4) inhibited both SARS-CoV-2-induced humoral and cellular immune responses. Furthermore, the magnitude of humoral and cellular immune response was dependent on the age and decreased over time. The RNA vaccines and ChAdOx1s vaccine effectively increased the level of anti-S antibodies. |
| first_indexed | 2024-04-11T10:07:27Z |
| format | Article |
| id | doaj.art-85e1bfa9fe984c819bd538cc1f2cf354 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T10:07:27Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-85e1bfa9fe984c819bd538cc1f2cf3542022-12-22T04:30:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.960001960001Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritisDora Nemeth0Dora Nemeth1Dora Nemeth2Hajnalka Vago3Hajnalka Vago4Laszlo Tothfalusi5Zsuzsanna Ulakcsai6David Becker7Zsofia Szabo8Bernadett Rojkovich9Bela Merkely10Bela Merkely11Gyorgy Nagy12Gyorgy Nagy13Gyorgy Nagy14Gyorgy Nagy15Department of Rheumatology and Clinical Immunology, Semmelweis University, Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, Budapest, HungaryDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, HungaryHeart and Vascular Center, Semmelweis University, Budapest, HungaryDepartment of Sports Medicine, Semmelweis University, Budapest, HungaryDepartment of Pharmacodynamics, Semmelweis University, Budapest, HungaryHeart and Vascular Center, Semmelweis University, Budapest, HungaryHeart and Vascular Center, Semmelweis University, Budapest, HungaryDepartment of Laboratory Medicine, Semmelweis University, Budapest, HungaryBuda Hospital of the Hospitaller Order of Saint John of God, Budapest, HungaryHeart and Vascular Center, Semmelweis University, Budapest, HungaryDepartment of Sports Medicine, Semmelweis University, Budapest, HungaryDepartment of Rheumatology and Clinical Immunology, Semmelweis University, Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, Budapest, HungaryDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, HungaryHeart and Vascular Center, Semmelweis University, Budapest, HungaryBackgroundTo investigate the factors that have significant impact on the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection and vaccination induced immune response in rheumatoid arthritis (RA).MethodsSerological response was measured by quantifying anti-SARS-CoV-2 specific antibodies, while the cell-mediated response was measured by a whole-blood test quantifying the interferon (IFN)-γ response to different SARS-CoV-2-specific domains.ResultsWe prospectively enrolled 109 RA patients and 43 healthy controls. The median time (IQR) between the confirmed infection or the last vaccination dose and the day when samples were taken (“sampling interval”) was 3.67 (2.03, 5.50) months in the RA group. Anti-Spike (anti-S) specific antibodies were detected in 94% of RA patients. Among the investigated patient related variables, age (p<0.004), sampling interval (p<0.001), the brand of the vaccine (p<0.001) and targeted RA therapy (TNF-inhibitor, IL-6 inhibitor, anti-CD20 therapy) had significant effect on the anti-S levels. After covariate adjustment TNF-inhibitor therapy decreased the anti-S antibody concentrations by 80% (p<0.001). The same figures for IL-6 inhibitor and anti-CD20 therapy were 74% (p=0.049) and 97% (p=0.002), respectively. Compared to subjects who were infected but were not vaccinated, the RNA COVID-19 vaccines increased the anti-S antibody levels to 71.1 (mRNA-1273) and 36.0 (BNT162b2) fold (p<0.001). The corresponding figure for the ChAdOx1s vaccine is 18.1(p=0.037). Anti-CCP (anti-cyclic citrullinated peptides) positive patients had 6.28 times (p= 0.00165) higher anti-S levels, than the anti-CCP negative patients. Positive T-cell response was observed in 87% of the healthy volunteer group and in 52% of the RA patient group. Following vaccination or infection it declined significantly (p= 0.044) but more slowly than that of anti-S titer (6%/month versus 25%). Specific T-cell responses were decreased by 65% in patients treated with anti-CD20 therapy (p=0.055).ConclusionOur study showed that the SARS-CoV-2-specific antibody levels were substantially reduced in RA patients treated with TNF-α-inhibitors (N=51) and IL-6-inhibitor (N=15). In addition, anti-CD20 therapy (N=4) inhibited both SARS-CoV-2-induced humoral and cellular immune responses. Furthermore, the magnitude of humoral and cellular immune response was dependent on the age and decreased over time. The RNA vaccines and ChAdOx1s vaccine effectively increased the level of anti-S antibodies.https://www.frontiersin.org/articles/10.3389/fimmu.2022.960001/fullCOVID-19rheumatoid arthritisantibody responseT-cell responsevaccinationDMARD (disease-modifying antirheumatic drug treatment) |
| spellingShingle | Dora Nemeth Dora Nemeth Dora Nemeth Hajnalka Vago Hajnalka Vago Laszlo Tothfalusi Zsuzsanna Ulakcsai David Becker Zsofia Szabo Bernadett Rojkovich Bela Merkely Bela Merkely Gyorgy Nagy Gyorgy Nagy Gyorgy Nagy Gyorgy Nagy Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis Frontiers in Immunology COVID-19 rheumatoid arthritis antibody response T-cell response vaccination DMARD (disease-modifying antirheumatic drug treatment) |
| title | Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis |
| title_full | Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis |
| title_fullStr | Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis |
| title_full_unstemmed | Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis |
| title_short | Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis |
| title_sort | factors influencing the sars cov 2 infection and vaccination induced immune response in rheumatoid arthritis |
| topic | COVID-19 rheumatoid arthritis antibody response T-cell response vaccination DMARD (disease-modifying antirheumatic drug treatment) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.960001/full |
| work_keys_str_mv | AT doranemeth factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT doranemeth factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT doranemeth factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT hajnalkavago factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT hajnalkavago factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT laszlotothfalusi factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT zsuzsannaulakcsai factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT davidbecker factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT zsofiaszabo factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT bernadettrojkovich factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT belamerkely factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT belamerkely factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT gyorgynagy factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT gyorgynagy factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT gyorgynagy factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis AT gyorgynagy factorsinfluencingthesarscov2infectionandvaccinationinducedimmuneresponseinrheumatoidarthritis |